chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Miscarriage 1 week after vaccine "On 10/5/21 I had an ultrasound and they said they saw the yolk sac and gestational sac, however there was no fetal pole or heartbeat. They wanted me to wait 11 days to have another ultrasound in case my dates were off or it was just too early. So on 10/18/21 I had the 2nd ultrasound and was diagnosed with a miscarriage. They suspected the baby died/stopped growing the same week of the first ultrasound. I then was given medication to induce the miscarriage on 10/20/21.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Sep2022 as dose 5 (booster), single (Lot number: GH9694), in left arm and on 21Apr2023 at 10:00 as dose 6 (booster), single (Lot number: GL2042) at the age of 68 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 02Feb2021 as dose 1, single (Lot number: EN5318), in left arm, on 02Mar2021 as dose 2, single (Lot number: EN6199), in left arm, on 27Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm and on 01Apr2022 as dose 4 (booster), single (Lot number: FK9895), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Clinical depression type 2 diabetes" (unspecified if ongoing); "Clinical depression type 2 diabetes" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Compazine, reaction(s): "Known Allergies: Compazine". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 12Jun2023, outcome "not recovered" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical course: Patient had Paxlovid treatment from 15Jun2023 to 19Jun2023.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300231366 same patient, different drug/events;US-PFIZER INC-202300231837 same patient, different vaccine dose/event;US-PFIZER INC-202300232002 same patient, different vaccine dose/event;US-PFIZER INC-202300232003 same patient, different vaccine dose/event;US-PFIZER INC-202300232004 same patient, different vaccine dose/event;US-PFIZER INC-202300232005 same patient, different vaccine dose/event;US-PFIZER INC-202300232006 same patient, different vaccine dose/event;
This spontaneous report was received from a registered pharmacist concerning to a patient of unknown age and gender. Medical history and drug reactions or allergies were not reported. On 11-SEP-2013, the patient was vaccinated with PNEUMOVAX23 lot # 6720747/1502AA, expiration date 19-MAY-2013 intramuscular (dose not reported). Concomitant therapy was not reported. On 11-SEP-2013, the patient was administered an expired dose of PNEUMOVAX23 and no adverse effect was reported. At the time of report, the patient's outcome was unknown. Additional information has been requested.
Tightness in the chest area, wheezing, dry cough, a shortness of breath, body aches, severe headaches, fatigue.
Patient states arm was not feeling normal after shot. A week ago it started to become itchy and now it is red and hot. I advised patient to call their medical doctor today to get an appointment
arm pain; mouth had ulcerations; Unusual taste sensations; tongue felt swollen; tiredness; headache/her head would be pounding; Weird coating on tongue; This is a spontaneous report from a contactable consumer (patient). A 66-year-old female patient received her first dose of bnt162b2 (BNT162B2 reported as PFIZER-BIONTECH COVID-19 VACCINE; lot number: EN5318; expiration date: unknown) at 66-year-old vaccination age intramuscularly administered in the left arm on 01Feb2021 as a single dose for covid-19 immunisation. Medical history included obesity just barely qualifies under that began 6 years ago (2015), allergy to one type of Penicillin VK and blood pressure (blood pressure abnormal). The patient has no familial medical history. Concomitant medication included losartan start and stop date were unknown for blood pressure. The patient has no previous immunization with the Pfizer vaccine considered as suspect and did not have other additional vaccines administered on the same day as the covid-19 vaccine. The patient reported that he experienced mouth ulcerations, tongue swelling, arm pain, tiredness and headache. The patient further reported that for the first day or two (02Feb2021 09:00), she had tiredness and headache and that was all resolving. Then on 04Feb2021 06:00, she woke up and the rest of her mouth had ulcerations. Her tongue felt swollen and she had a really weird coating on tongue (also reported to have started on 02Feb2021 06:00), along with really unusual taste sensations that lasted for 4 days and calmed down. It is still continuing on a very reduced level. She is still having weird problems with taste and her tongue feels different. She stated that the tiredness improved on 03Feb2021 and the headache was intermittent until 05Feb2021. The tongue swelling has not resolved all the way, it is intermittent. She will feel ok one day, and the next day, it will be back. She mentioned that the patchy white coating on tongue only lasted about a day, but she still has the feeling intermittently along with the taste sensations, but the white part is gone. The patient also stated that when she would wake up in the morning, her head would be pounding. That is the kind of symptoms she would have if she didn't take her blood pressure medication, but she did take her medication. The patient had arm pain on an unspecified date. The outcome of the event taste abnormality was not recovered, as for the event arm pain was unknown while the outcome of the other events was recovering.
pt had a positive COVID test on 1/1/22 and was admitted to Hospital with COVID pneumonia with AHRF and superimposed bacterial pneumonia, treated with IV ABX, dc'd to Transitional Care on 1/31/22; 2/9/22 to ED for evaluation; pt had occasional N/V with constipation; admitted; testing showed acute cholecystitis, Pneumonia due to COVID with superimposed bacterial pneumonia, AHRF, pulmonary fibrosis; treated with O2 and IV ABX therapy; pt's condition worsened; DNI; transitioned to comfort care and passed away in the hospital
Also reported a heart attack following their second Pfizer vaccine shot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An elderly male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MYOCARDIAL INFARCTION (medically significant), outcome "unknown", described as "Also reported a heart attack following their second Pfizer vaccine shot". Clinical course: Patient received a COVID-19 monovalent booster (manufacturer not specified) and had a mild case of COVID-19 "sometime afterwards". Also reported a heart attack following their second Pfizer vaccine shot (Reporter is unsure if this was referring to primary series or booster).  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Information has been received from a nurse practioner concerning a female patient (age not reported) who on an unspecified date was vaccinated with HPV rL1 6 11 16 18 VLP vaccine (yeast) (Lot# not provided). Subsequently, the patient fainted post vaccination. She stated that it "felt like the medicine traveled through my system at time of injection". Subsequently, the patient recovered from the syncope and abnormal feeling. The nurse reported that the patient was not disoriented, was very aware and her blood pressure (actual BP not reported) was within normal limits. The patient was offered a sugar drink (soda) after the event and recovered from the event. The nurse practitioner noted that the patient had eaten before coming in for the vaccination. Additional has been requested. 01/05/2007 Information has been received from a nurse practitioner concerning a 22 year old female patient who on 06-SEP-2006 at 14:00 was vaccinated with the first dose of GARDASIL (Lot# 653650/0640F). Subsequently, the patient fainted 30 minutes post vaccination. She stated that it "felt like the medicine traveled through my system at time of injection". Subsequently, the patient recovered from the syncope and abnormal feeling. The nurse reported that the patient was not disoriented, was very aware and her blood pressure (actual BP not reported) was within normal limits. The patient was offered a sugar drink(soda) after the event and recovered from the event. The nurse practitioner noted that the patient had eaten before coming in for the vaccination. Additional information has been requested.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In 2014, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided), at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. In 2015, the patient was treated at a hospital for a persistent and severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome is unknown. Additional information has been requested.
Vomiting, constipated, abdominal pain. Treatment - surgery for intussusception.  04/16/2007 MR received for 2 night hospitalization 3/3-5/2007 for a 6 day h/o crampy abdominal pain, lack of bowel movement, and vomiting. Partial reduction of the intussusception was completed, however focal intussusception remained in the distal terminal ileum which was surgically reduced via open reduction. Discharge DX:  Intussusception.
Redness that extended down arm. Warm to touch. Still present 3 days after the vaccine was given.
Redness over upper body; Rash over upper body; This case was reported by a pharmacist via call center representative and described the occurrence of erythema in a 61-year-old female patient who received Herpes zoster (Shingrix) (batch number 9KT7T, expiry date 31st March 2021) and (batch number 5S34K, expiry date 31st March 2021) for prophylaxis.   On 15th July 2019, the patient received Shingrix. On an unknown date, the dose was an unknown dose. On 2nd August 2019, 18 days after receiving Shingrix, the patient experienced erythema and rash. On an unknown date, the outcome of the erythema and rash were unknown.   It was unknown if the reporter considered the erythema and rash to be related to Shingrix.  Additional details were provided as follows: The pharmacist reported that the patient was administered Shingrix vaccine and on the day of reporting was experiencing a rash and redness over her upper body. The reporter gave consent to follow up.
Swollen left upper leg/thigh 38cm; right leg 31cm. Reaction to DTAP. R/o cellulitis. Pt was afebrile. Treated with Rocephin, 1 gram, right thigh, in office. Sent to ER the same afternoon. Right thigh, parents claims, is increased in swelling.
+COVID via saliva PCR testing 4/2/2021 symptomatic  with rhinorrhea starting 3/31/21 Patient is physician but exposure was his children
2 cm swelling from an injection in R deltoid on 12-13-05.  Mother noticed it day of injection.  Decreasing in size.  redness and warmth.  Rash noted on trunk-more pronounced on back.  Slept most of day on 12-16-05.  Had 2 injections in each arm L and R.
Varicella Vaccine breakthrough. Diagnosed with varicella on 5-14-10 - 20 lesions seen - no fever.
Patient experienced large bruising on the shoulder and upper arm and generalized soreness.  Patient was uncomfortable for a few days.
PATIENT HAD RED, SWOLLEN ARM AND SITE OF INJECTION, PATIENT TOOK SOME BENADRYL AND APPLIED CORTISONE.
T 98.0 degree rash on left arm surrounding smallpox vaccination site. Started 2 days ago 14 JAN 09, spread to axilla area, swelling in axilla area, tenderness to touch, no meds used ; states rash much improved. No fever, no chills, seen at 16 JAN 09. Sick call.  Prescription for BENADRYL and IBUPROFEN.
This is a spontaneous report from a contactable consumer reported for himself. This 65-year-old male patient received in Mar2017 a single dose of PREVNAR 13 as injection in the left arm since had a cough and thought would help. Medical history included ongoing diabetes since 2015, ongoing blood pressure high since 2017, ongoing high cholesterol and high triglycerides since 2010 and sleep disorder. Concomitant medications included ongoing gemfibrozil and metformin for diabetes, ongoing atorvastatin calcium, ongoing lisinopril, zolpidem tartrate (AMBIEN) for sleep disorder, ongoing glimepride and insulin. The patient reported that in Mar2017 when he got the injection he had severe pain in the left arm where the injection site was which has continued up until now. Within 24hrs he had pain in joints and muscles. His left arm now hurts severely in the evenings from his joints down from his shoulder to fingers. It hurts in his wrist and shoulder. It continued to hurt at the site of injection. He has limited arm motion with left arm. He cannot use the left arm to reach up when in the grocery store. The pain has radiated from the shoulder to finger tips. He has had X-Rays of the arm (date not reported) and he will have a CAT scan of the left arm. He has never had pain like this. He had soreness and redness on injection. No longer has the redness. It went away a few weeks (unknown date in 2017). All events started within 24HRS of receiving the vaccine (Mar2017). Completely recovered from the redness. All other events were not recovered.
they had multiple vaccine MRNA-injured people in her family.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID.  A male patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INJURY (non-serious), outcome "unknown", described as "they had multiple vaccine MRNA-injured people in her family.".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient found to have splenanegaly (5 cm below costal margin) 10 days after vaccination.  Concurrently had fever and URI symptoms but nothing suggesting of BBV infection, including normal CBC.
Minor itching on cheeks; Sore arm; Headache; This is a spontaneous report from a contactable consumer or other non health professional. This consumer reported for the patient in response to consumer letter. A 82-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL8982, Expiration date not reported), via an unspecified route of administration on 29Jan2021 (at the age of 82 years) as dose 2, single for covid-19 immunization. The patient medical history was not reported. Concomitant medication included triamterene, verapamil, levothyroxine, and atorvastatin, all taken for an unspecified indication from an unspecified start date and ongoing. Patient previously took first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EK9231, Expiration date not reported), via an unspecified route of administration in right arm on 08Jan2021 (at the age of 82 years) as dose 1, single for covid-19 immunization and experienced reaction in mouth broke out in tiny sores, facial flushing, sore arm, and mild headache. Before vaccination, patient took Benadryl for unspecified indication and was required to wait 40minutes. On an unknown date, the patient experienced minor itching on cheeks, sore arm and mild headache. The nurse recommended treatment with loratadine allergy medication, which patient took before bed, and another one the next evening. The treatment relieved facial itching. The outcome of all the events was unknown.
18FEB92 took 8 ox of Isomil @ 1245pm recvd vax 130pm; vomited once @ 250pm & again @ 305pm; mom notified MD;
Narrative:  39 yo female with PMH GERD, DM2, Crohn's disease, obesity, and  plantar fasciitis who presented to urgent care on 3/15/2021 due to swelling and  erythema of injection site along with a lump under her arm where she received her second dose of pfizer. Patient received her first dose on 2/20 with no issue. She received the second dose on 3/12/2021. #LAD secondary to COVID vaccine- Patient with erythema and tenderness and lymphadenopathy consistent with  reaction to COVID vaccine. - No systemic symptoms at this point, though erythema has progressively increased since Friday. -Favor adverse reaction to vaccine vs.  cellulitis or abscess at this point Plan: -Symptomatic cares at this point, tylenol,  ice, rest. -Prescribed lidocaine patch for pain, apply 12 hours on/12 hours off. -No antibiotics at this time, instructed patient to return to clinic if begins developing  fevers or other systemic symptoms or purulent discharge. - If patients returns, would favor initiating antibiotics
pain on left side of face from temple, through jaw, down the neck on 29Sep (swollen lymph nodes); pain on left side of face from temple, through jaw, down the neck on 29Sep (swollen lymph nodes); pain on left side of face from temple, through jaw, down the neck on 29Sep (swollen lymph nodes); pain on left side of face from temple, through jaw, down the neck on 29Sep (swollen lymph nodes); Jaw was throbbing; Persistent headache: center forehead on Saturday, back of head on Sunday, perimeter/ring of head Monday-Tuesday; Experienced nausea w/brief period of gagging; Blood pressure reading was 136/77 (higher than normal); Fever (100.2) for two days (Sat &Sun); 99 degrees for 1 day (Mon); Sore arm (Mon-Thurs); Chills for two days (Sat & Sun); body ache 1 day (Sat); This is a spontaneous report from a non-contactable consumer (patient). A 43-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: 301308A) via an unspecified route of administration, administered in left arm on 24Sep2021 (at the age of 43-year-old) as dose 1, single for COVID-19 immunization. Medical history included COVID and lupus. No known allergies. Concomitant medication included hydroxychloroquine sulfate (PLAQUENIL [HYDROXYCHLOROQUINE SULFATE]). The patient had COVID prior vaccination and not tested for COVID post vaccination. No other vaccine in four weeks. On 25Sep2021 10:00, the patient experienced fever (100.2) for two days (Sat & Sun); 99 degrees for 1 day (Mon), sore arm (Mon-Thu), chills for two days (Sat & Sun), body ache 1 day (Sat), nausea w/brief period of gagging, blood pressure reading was 136/77 (higher than normal). On 28Sep2021, the patient experienced persistent headache: center forehead on Saturday, back of head on Sunday, perimeter/ring of head Monday-Tuesday. On 29Sep2021, the patient experienced pain on left side of face from temple, through jaw, down the neck (swollen lymph nodes) and jaw was throbbing. The patient underwent lab tests and procedures which included blood pressure: higher (136/77) on 28Sep2021 and fever: 99 degrees on an unspecified date in Sep2021, fever: 100.2 on 24Sep2021. The patient was treated with 20 mg of Prednisone 2x/day for 5 days for treating all the events. Physician Office Visit-Yes. On an unspecified date in Sep2021, the patient recovered from fever (100.2) for two days (Sat & Sun); 99 degrees for 1 day (Mon), chills for two days (Sat & Sun) and body ache 1 day (Sat) and in 2021 sore arm (Mon-Thu) was recovered. The outcome of all other events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
didn't have hearing; lost his balance, didn't have equilibrium; Caller had a Pfizer booster; would have been falling many times; Lost 20 lbs; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (159558). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 06Dec2021 (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose Unknown, Manufacturer Unknown), for COVID-19 Immunization. The following information was reported: IMMUNISATION (medically significant) with onset 06Dec2021, outcome "unknown", described as "Caller had a Pfizer booster"; DEAFNESS (medically significant), outcome "unknown", described as "didn't have hearing"; BALANCE DISORDER (non-serious), outcome "unknown", described as "lost his balance, didn't have equilibrium"; FALL (non-serious) with onset 2021, outcome "unknown", described as "would have been falling many times"; WEIGHT DECREASED (non-serious) with onset 2021, outcome "unknown", described as "Lost 20 lbs". The patient underwent the following laboratory tests and procedures: weight: 20 lbs, notes: Lost.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
vaccine was administered subcutaneously rather than the recommended intramuscular.  no adverse reaction was reported